<DOC>
	<DOCNO>NCT02980809</DOCNO>
	<brief_summary>The purpose study determine whether topotecan plus apatinib superior topotecan alone second-line therapy small-cell lung cancer .</brief_summary>
	<brief_title>Topotecan Plus Apatinib Versus Topotecan Alone Second-line Therapy Small-cell Lung Cancer</brief_title>
	<detailed_description>Small-cell lung cancer ( SCLC ) aggressive tumor patient experience relapse progression standard chemotherapy . Topotecan active second-line therapy SCLC patient . However , even sensitive patient , 20 % response rate median time progression 12 week observe . New therapeutic option SCLC need . Apatinib small-molecule tyrosine kinase inhibitor inhibit vascular endothelial growth factor receptor 2 . It approve patient advanced gastric cancer refractory two line prior chemotherapy . The efficacy apatinib SCLC unknown . The purpose study determine whether topotecan plus apatinib superior topotecan alone second-line therapy small-cell lung cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>limited extensivestage SCLC fail firstline therapy ≥18 year old Eastern Cooperative Oncology Group performance status ≤2 least one measurable lesion define RECIST ( version 1.1 ) least one measurable lung tumor lesion WBC count ≥3,500/μL , neutrophils ≥1,500μL , platelets ≥100,000μL , hemoglobin ≥ 9.0 g/dL AST , ALT ≤2 × upper limit normal ≤5 × upper limit normal liver metastasis . symptomatic CNS metastasis concomitant previous malignancy within last 5 year severe comorbidities ; prior topotecan therapy hypersensitivity contraindication study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>